TORONTO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today issued the following letter to shareholders from Thomas Looby, President and Chief Executive Officer.
Dear Shareholders,
Years of development have now translated into U.S. commercial clinical use. Over the past year, Conavi achieved four milestones that establish the foundation for OCTIV™, powered by Novasight™:
- FDA 510(k) clearance for our next-generation hybrid imaging system.
- Peer-reviewed clinical evidence illustrating how hybrid imaging can inform coronary treatment decisions.
- First U.S. commercial placement and clinically beneficial cases with OCTIV, followed by ongoing use by multiple physicians.
- Five-year extension of the Japan Lifeline credit facilities, moving maturity from April 2027 to April 2032.
Together, these achievements position Conavi to broaden physician adoption, expand hospital placements, grow recurring catheter utilization and attract strategic interest in our platform.
Clinical Evidence Supports Broader Adoption
OCTIV combines the imaging depth of intravascular ultrasound (“IVUS”) with the high-resolution detail of optical coherence tomography (“OCT”) in a single catheter to guide coronary interventions.
The 2025 U.S. acute coronary syndrome guidelines give IVUS or OCT a Class 1, Level of Evidence A recommendation for procedural guidance in patients with acute coronary syndromes undergoing stent implantation in the left main artery or complex lesions. Pooled randomized evidence shows lower risks of cardiac death, heart attacks, repeat interventions and stent thrombosis with intravascular imaging guidance than with angiography alone.
Our peer-reviewed case reports illustrate how hybrid imaging can inform treatment decisions:
- July case report. In the Journal of the Society for Cardiovascular Angiography & Interventions, physicians described using hybrid imaging to assess and treat a calcified lesion in a patient with impaired renal function, with IVUS-only imaging at selected stages helping to limit contrast exposure.
- September case report. In Catheterization and Cardiovascular Interventions, hybrid imaging helped physicians evaluate post-stent dissections and white thrombus, informing decisions on further stenting and medical management.
OCTIV Is in Ongoing Clinical Use
In November, we announced our first U.S. commercial placement and clinical cases, with Dr. Megha Prasad performing the initial cases. Approximately 25 clinical cases have been completed within the first two weeks of launch. Successful cases are continuing, with multiple physicians on the hospital’s team now using OCTIV.
OCTIV incorporates enhancements focused on image quality, catheter deliverability and ease of use. Its patient interface module sits outside the sterile field, and the catheter connection workflow is designed to simplify setup.
Strong Physician Demand Following Launch and TCT
Following our first U.S. clinical cases, we participated in Transcatheter Cardiovascular Therapeutics (“TCT”) 2026, where OCTIV received a strong reception. Clinical presentations and physician education sessions introduced its complementary imaging capabilities to a broader audience.
Demand for OCTIV systems now exceeds our current placement capacity. The response to our limited market release and initial clinical experience, as well as discussions at TCT have surfaced strong demand for OCTIV systems. We will work to meet this demand over time.
We also presented preclinical saline-based imaging results: 26 interpretable imaging pullbacks in three swine, without iodinated contrast during image acquisition. These findings support further evaluation of an approach that could help physicians manage contrast exposure.
Financial Flexibility Supports Commercial Expansion
- Japan Lifeline support. Backed by a relationship spanning more than a decade, the five-year extension better aligns our debt maturity with our commercial development plans.
- $1.75 million received under Ontario’s Life Sciences Scale-Up Fund, including a $1.25 million payment following FDA clearance. The agreement provides up to $2.5 million, subject to specified milestones, for eligible commercialization and manufacturing activities.
Our spending priorities are physician support, additional sites, reliable product supply and clinical evidence.
Clear Priorities for Growth
Our first U.S. placement and ongoing clinical cases are meeting and exceeding our expectations. Our priority now is to supply this strong, initial demand through carefully selected hospital placements, physician education and support for repeat use. Four priorities will guide our execution:
- Prioritize the next U.S. placements. Focus on hospitals where physician demand, procedural needs and operational readiness align.
- Grow catheter utilization. Build on ongoing use at our first U.S. site by supporting repeat procedures and training additional physicians.
- Generate clinical evidence. Build on our initial commercial cases and peer-reviewed reports to support further publications showing how hybrid imaging informs treatment decisions.
- Expand physician education and market awareness. Follow up on TCT discussions with targeted education, scientific meetings and direct engagement to help interested clinical teams integrate OCTIV into their workflows.
Building a Sustainable Commercial Business
This year, the essential pieces came together: regulatory clearance, published clinical evidence, ongoing U.S. commercial use and greater financial flexibility. We now have a clear foundation for growth.
We believe disciplined execution can strengthen Conavi’s commercial position, attract strategic interest in our platform and create lasting shareholder value.
To our employees, clinical collaborators, partners and shareholders, thank you for helping bring Conavi to this point. We look forward to sharing our progress as we expand OCTIV’s clinical and commercial reach.
Sincerely,
Thomas Looby
President and Chief Executive Officer
Conavi Medical Corp.
About Conavi Medical
Conavi Medical Corp. is a commercial-stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its OCTIV™ hybrid imaging system combines intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) to provide simultaneous, co-registered images of coronary arteries using a single imaging catheter. These complementary imaging modalities provide physicians with information to support treatment decisions during coronary interventions. For more information, visit www.conavi.com.
Forward looking information
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the anticipated clinical benefits and performance of OCTIV, continued clinical use, placements at additional U.S. institutions, plans to expand physician adoption, system utilization and recurring catheter revenue, the potential to attract strategic interest, further evaluation of saline-based hybrid imaging, the anticipated benefits of the credit facility maturity extension, the continued commercialization and U.S. rollout of Conavi's hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to execute its commercial development plans, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company's profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Contact
Mark Quick, Chief Financial Officer | 416-483-0100
Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com
Susan Thomas, Media | 619-540-9195



© 2026 Canjex Publishing Ltd. All rights reserved.